SEC Form 4 · accession 0002151661-26-000004
Vaxcyte, Inc. · PCVX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Luis Jodar
Officer — Chief Medical Officer
Period of report
Sep 4, 2026
Accepted (ET)
Sep 9, 2026 · 5:40 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001649094
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 4, 2026 | A | 52,632 | $0.00 | A | 52,632 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $61.16 | Sep 4, 2026 | A | 88,254 | A | — | Sep 4, 2036 | Common Stock | 88,254 | 88,254 | D |
Explanation of responses
- F1Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 1/4 of the shares subject to the award on September 7, 2027 and 1/8 of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
- F21/4 of the shares subject to the option shall vest on August 31, 2027, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.